

RICT 2012 - Interfacing Chemical Biology and Drug Discovery

Programme

Confirmed Plenary Speakers (to Date)

Confirmed speakers

RICT 2012 - Interfacing Chemical Biology and Drug Discovery

Programme

Wednesday July 4, 2012

08:00 Registration

09:00 Welcome session

Session 1: Case Studies (Kinase)

Session Chairman

Dr Pascal GEORGE
(SCT & INDEPENDENT SCIENTIFIC EXPERT & ADVISER, Longvilliers, France)

09:15 Translating Structural-biology & Preclinical Activity of Nilotinib into Efficacy in Leukemia Patients

Dr Paul W. MANLEY
(NOVARTIS PHARMA, Basel, Switzerland)

10:00 Matched Triplicate Design Sets in the Optimisation of a New Series of Glucokinase Activators

Prof. Mike WARING
(ASTRAZENECA, Newcastle upon Tyne, United Kingdom)

10:45 Coffee Break

Session 2: Non Classical Drugs

Session Chairman

Dr Samir JEGHAM
(SANOFI R&D, MONTPELLIER, France)

11:15 Synthetic Carbohydrates in the Search for Tailor-made Antibacterial Vaccines: Shigellosis as a Challenge

Dr Laurence MULARD
(PASTEUR INSTITUTE, Paris, France)

12:00 Bicyclic Peptide Antagonists Isolated From Phage Display Libraries

Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

12:45 Lunch and Poster Presentation

Session Chairman

Prof. Vincent LISOWSKI
(UNIVERSITÉ DE MONTPELLIER 1, Montpellier, France)

**14:15 A Look at Some Innovative Chemical Aspects in Medicinal Chemistry, about Heterocycles, Microwaves, Chemical Libraries, Boronics and Garlands
Paul Ehrlich Prize Lecture**

Prof. Sylvain RAULT
(UNIVERSITÉ DE CAEN, Caen Cedex, France)

Session 3: Targeted Therapies

Programme

Session Chairman

Prof. Jean-Pierre GESSON
(UNIVERSITÉ DE POITIERS, Poitiers, France)

15:00 Squalenoyl Nanomedicines as Potential Therapeutics

Dr Didier DESMAËLE
(UNIVERSITÉ PARIS SUD, Châtenay-Malabry, France)

15:45 Coffee Break and Poster Session

Session Chairman

Prof. Jean-Pierre GESSON
(UNIVERSITÉ DE POITIERS, Poitiers, France)

16:15 Protein-binding Prodrugs and Drug Conjugates in Oncology: From Design, Applications to Combination Therapy

Prof. Felix KRATZ
(TUMOR BIOLOGY CENTER, Freiburg, Germany)

17:00 Potent Antibody Drug Conjugates for Cancer Therapy: From the Lab to a Clinically Approved Drug

Dr Peter SENTER
(SEATTLE GENETICS, Bothell, United States)

17:45 Final Announcements

18:00 Booster Presentations Exhibitors

Programme

Thursday July 5, 2012

Session Session 4: Case Studies (mGLU)

Session Chairman

Dr Luc VAN HIJFTE
(SCT & NOVALIX, Nijmegen, The Netherlands)

09:00 JNJ-42153605: A Novel Positive Allosteric Modulator of mGluR2 for the Treatment of CNS Disorders

Dr Jose CID
(JANSSEN RESEARCH AND DEVELOPMENT, Toledo, Spain)

09:45 Progress on Allosteric Modulation of mGluR5 and mGluR4: towards New Treatment Paradigms in Parkinson's Disease

Dr Jean-Philippe ROCHER
(ADDEX THERAPEUTICS, Plan-les-Ouates, Switzerland)

Session Session 5: Targets and Pathways

Session Chairman

Prof. Dario NERI
(ETH ZÜRICH, Zürich, Switzerland)

09:00 A Yeast-based Model for Prion Disease Allowed Isolation of Specific and Competitive Inhibitors of a New Protein Chaperone Activity Borne by the Ribosome that are Active Against Other Amyloid-based Diseases

Prof. Marc BLONDEL
(INSERM, Brest, France)

09:45 Structure and Function of Acid-Sensing Ion Channels

Dr Stephan KELLENBERGER
(UNIVERSITÉ DE LAUSANNE, Lausanne, Switzerland)

10:30 Coffee Break and Poster Session

Session Session 6: Epigenetics

Session Chairman

Prof. Yves CENATIEMPO
(UNIVERSITÉ DE POITIERS, Poitiers Cedex, France)

11:00 DNA Methylation Inhibitors In Cancer: Recent and Future Approaches

Dr Paola B. ARIMONDO
(INSTITUT PASTEUR - CNRS, Paris, France)

11:45 From ApoA1 Upregulation to BET Family Bromodomain Inhibition: Unlocking the Potential of an Epigenetic Target Class

Dr Olivier MIRGUET
(GLAXOSMITHKLINE, Les Ulis, France)

Session Session 7: New Tools / Platforms

Session Chairman

Dr Olivier LAVERGNE
(., Palaiseau, France)

11:00 Accelerating Drug Discovery through High Throughput Medicinal Chemistry - Alternative Lead Finding & Optimisation Approaches Including Representative Project Examples

Dr Werngard CZECHTIZKY
(SANOFI, Frankfurt am Main, Germany)

11:45 Combined Use of Noncovalent Mass Spectrometry and Other Biophysical Techniques in Early-stage Drug Discovery

Dr Jean-Paul RENAUD
(NOVALIX, Ostwald, France)

12:30 Lunch and Poster Session

Programme

Session Session 8: Exploring Chemical Space-Fragments

Session Chairman

Prof. Janos SAPI
(SCT & UNIVERSITY OF REIMS-CHAMPAGNE-ARDENNE, Reims, France)

- 14:00 Pharmacophore-based Parallel in Silico Screening: An Interesting Concept for Efficient Activity Profiling in Drug Discovery**

Prof. Thierry LANGER
(PRESTWICK CHEMICAL, Vienna, Austria)

- 14:45 Reduce to the Max – Probing Biology with Natural Product Fragments**

Prof. Karl GADEMANN
(UNIVERSITY OF BASEL, Zürich, Switzerland)

- 15:30 Chemical space exploration via Natural Product-like compounds**

Dr Jean-Yves ORTHOLAND
(EDELIRIS, Lyon, France)

Session Session 9: Case Studies (CNS)

Session Chairman

Dr Edmond DIFFERDING
(DIFFERDING CONSULTING, Louvain-la-Neuve, Belgium)

- 14:00 Sometimes You Just Have to Break the Rules ..**

Dr Yves P. AUBERSON
(NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

- 14:45 Discovery of RG1678, a First in Class Glycine Reuptake Inhibitor for the Treatment of Schizophrenia**

Dr Emmanuel PINARD
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

- 15:30 SV2 Proteins Beyond Levetiracetam: The Discovery of the First SV2C Selective Ligands**

Dr Anne VALADE
(UCB, Braine-l'Alleud, Belgium)

- 16:15 Coffee Break and Poster Session**

Session Chairman

Dr Pascal GEORGE
(SCT & INDEPENDENT SCIENTIFIC EXPERT & ADVISER, Longvilliers, France)

- 17:00 Two Chemical/Biological Approaches to Alzheimer's Disease: Prevention and Therapy
Charles Mentzer Prize Lecture**

Dr Laurent MEIJER
(MANROS THERAPEUTICS, Roscoff, France)

- 17:45 Final Announcements**

- 18:00 Booster Presentations**

Programme

Friday July 6, 2012

Session 10: Case Studies (Kinase)

Session Chairman

Dr Bernat VIDAL
(ALMIRALL, Barcelona, Spain)

08:45 Antagonists of the p53/hdm2 Protein-Protein Interaction - Path to the Clinic

Dr Carlos GARCIA-ECHEVERRIA
(SANOFI, Vitry sur Seine, France)

09:30 Sorafenib – A Signal Transduction Inhibitor for the Treatment of Liver Cancer

Dr Bernd RIEDL
(BAYER PHARMA, Wuppertal, Germany)

10:15 Coffee Break and Poster Session

Session Chairman

Dr. Vincent DIVE
(CEA, Gif-sur-Yvette, France)

10:45 Poster Awards and Labex Presentations

11:30 Session 11: Future trends in MedChemBio

Session Chairman

Prof. Joachim MITTENDORF
(BAYER PHARMA AG, Wuppertal, Germany)

11:30 Perspectives in Structure and Fragment Based Drug Discovery

Prof. Rod HUBBARD
(UNIVERSITY OF YORK / VERNALIS, York, United Kingdom)

12:15 Targeting Protein Interactions Mediated by Epigenetic Acetyl-lysine Reader Domains of the Bromodomain Family

Prof. Stefan KNAPP
(OXFORD UNIVERSITY, Oxford, United Kingdom)

13:00 Final Conclusions

13:15 Lunch

14:00 End of Symposium